Research programme: TIE 2 receptor kinase inhibitors - PfizerAlternative Names: CE-355774; PF-371989
Latest Information Update: 13 Aug 2009
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action TIE 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Aug 2009 This programme is still in active development
- 29 Sep 2006 Preclinical trials in Cancer in USA (unspecified route)